Bryostatin-1 Effect on HIV-1 Latency and Reservoir HIV-1 Infected Patients Receiving Antiretroviral Treatment: Pilot, Controlled, Double Blinded, Dose Searching Trial

Trial Profile

Bryostatin-1 Effect on HIV-1 Latency and Reservoir HIV-1 Infected Patients Receiving Antiretroviral Treatment: Pilot, Controlled, Double Blinded, Dose Searching Trial

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs Bryostatin-1 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BRYOLAT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Feb 2016 Primary endpoint of intracellular HIV-1 RNA (usRNA and msRNA) level before and after bryostatin-1 administration has not been met, according to results presented at the 23rd Conference on Retroviruses and Opportunistic Infections.
    • 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top